Mia Sisic1, Joslyn S Kirby2, Sanwarjit Boyal3, Lisa Plant1, Chelsea McLellan1, Jerry Tan3,4. 1. 1 Department of Psychology, University of Windsor, Windsor, Ontario, Canada. 2. 2 Penn State Hershey Dermatology, Hershey, PA, USA. 3. 3 Windsor Clinical Research, Inc, Windsor, Ontario, Canada. 4. 4 Department of Medicine, University of Western Ontario, London, Ontario, Canada.
Abstract
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic skin disorder with adverse impacts on both physical and psychosocial well-being. There is presently no validated HS-specific quality-of-life (QoL) measure. OBJECTIVE: The objective of this study is to develop a QoL instrument for HS (HS-QoL) in accordance with recommended standards. METHODS: Patient interviews (concept elicitation) and expert input were used to develop the conceptual framework for outcomes perceived important to patients with HS. A HS-QoL-v1 measure was developed, and cognitive interviews with patients were conducted for pilot testing. RESULTS: Concept elicitation interviews with patients with HS (n = 21) generated 12 themes. Most frequently reported were impacts on daily activities and symptoms due to HS. These themes, along with literature review and input from clinical experts, informed development of the HS-QoL-v1. Nine cognitive interviews were conducted in a pilot test and resulted in the HS-QoL-v2 measure. CONCLUSION: The HS-QoL-v2 is a preliminary QoL instrument for which further psychometric validation and establishment of clinimetric properties will be undertaken.
BACKGROUND:Hidradenitis suppurativa (HS) is a chronic skin disorder with adverse impacts on both physical and psychosocial well-being. There is presently no validated HS-specific quality-of-life (QoL) measure. OBJECTIVE: The objective of this study is to develop a QoL instrument for HS (HS-QoL) in accordance with recommended standards. METHODS:Patient interviews (concept elicitation) and expert input were used to develop the conceptual framework for outcomes perceived important to patients with HS. A HS-QoL-v1 measure was developed, and cognitive interviews with patients were conducted for pilot testing. RESULTS: Concept elicitation interviews with patients with HS (n = 21) generated 12 themes. Most frequently reported were impacts on daily activities and symptoms due to HS. These themes, along with literature review and input from clinical experts, informed development of the HS-QoL-v1. Nine cognitive interviews were conducted in a pilot test and resulted in the HS-QoL-v2 measure. CONCLUSION: The HS-QoL-v2 is a preliminary QoL instrument for which further psychometric validation and establishment of clinimetric properties will be undertaken.
Entities:
Keywords:
HS-QoL; development; hidradenitis suppurativa (HS); impacts; measure; patient-reported outcomes (PRO); quality of life (QoL)
Authors: A J Onderdijk; H H van der Zee; S Esmann; S Lophaven; D N Dufour; G B E Jemec; J Boer Journal: J Eur Acad Dermatol Venereol Date: 2012-02-20 Impact factor: 6.166
Authors: J S Kirby; L Thorlacius; B Villumsen; J R Ingram; A Garg; K B Christensen; M Butt; S Esmann; J Tan; G B E Jemec Journal: Br J Dermatol Date: 2019-12-26 Impact factor: 9.302
Authors: Zarine S Patel; Lauren K Hoffman; Dawn C Buse; Amy S Grinberg; Ladan Afifi; Steven R Cohen; Michelle A Lowes; Elizabeth K Seng Journal: Curr Pain Headache Rep Date: 2017-11-01
Authors: Servando E Marron; Manuel Gomez-Barrera; Lucía Tomas Aragones; Ana Goni-Navarro; Eva Vilarrasa-Rull; Rosa María Diaz-Diaz; Francisco Javier Garcia-Latasa de Aranibar; Ricardo Campos-Rodenas; Victoria Fuentelsaz Del Barrio; Yolanda Gilaberte-Calzada; Tamara Gracia-Cazaña; Anna María Morales-Callaghan; Sandra Ros-Abarca; María Blanca Madrid-Alvarez; Lluís Puig Journal: Acta Derm Venereol Date: 2021-08-25 Impact factor: 3.875
Authors: Lourdes M Perez-Chada; Joseph F Merola; April W Armstrong; Amit Garg; John Latella; Alice B Gottlieb Journal: J Investig Dermatol Symp Proc Date: 2020-11
Authors: Piotr K Krajewski; Łukasz Matusiak; Esther von Stebut; Michael Schultheis; Uwe Kirschner; Georgios Nikolakis; Jacek C Szepietowski Journal: Life (Basel) Date: 2021-01-08
Authors: Piotr K Krajewski; Łukasz Matusiak; Marta Szepietowska; Julia E Rymaszewska; Gregor B E Jemec; Joslyn S Kirby; Jacek C Szepietowski Journal: Postepy Dermatol Alergol Date: 2020-07-14 Impact factor: 1.837
Authors: Pavel V Chernyshov; Andrew Y Finlay; Lucia Tomas-Aragones; Francoise Poot; Francesca Sampogna; Servando E Marron; Sergey V Zemskov; Damiano Abeni; Thrasyvoulos Tzellos; Jacek C Szepietowski; Christos C Zouboulis Journal: Int J Environ Res Public Health Date: 2021-06-06 Impact factor: 3.390